Chikungunya Vaccine Development in Africa Accelerated by ACT-CHIK
4 Articles
4 Articles
Paris, 8 Jun (EFE).- The Pasteur Institute of France announced this Monday the launch of a four-year international project to achieve a new chikungunya vaccine that will be accessible to endemic populations (especially those in Africa) and that will be provided with 15.3 million euros of European funds. "The 15.3 million euros of European funds for ACT-CHIK will boost the clinical development of MV-CHIK, a chikungunya vaccine based on the measle…
Chikungunya Vaccine Development in Africa Accelerated by ACT-CHIK
Institut Pasteur is launching ACT-CHIK (Accelerating Clinical Trials for CHIKungunya Vaccine in Africa), a four-year research project funded by the Global Health EDCTP3 Joint Undertaking under the European Union’s Horizon Europe program that aims to advance clinical trials and prepare for the manufacturing of a chikungunya vaccine in Africa. With €15.3 million in EU funding, ACT-CHIK will advance the development of MV-CHIK—a measles-virus-based …
Speeding Up Chikungunya Vaccine Development in Africa: Introducing the
In a groundbreaking advancement poised to reshape public health landscapes across Africa, the Institut Pasteur has unveiled the ACT-CHIK initiative—an ambitious €15.3 million project designed to accelerate the clinical development and regional manufacturing capabilities of a novel chikungunya vaccine tailored specifically for African populations. This four-year endeavor, funded by the Global Health EDCTP3 Joint Undertaking under the European Uni…
The idea is to make it accessible to populations in endemic areas with the goal of reducing the lack of equity in access to vaccination.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
